Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study
Purpose: To evaluate the long-term efficacy and safety of secukinumab in pediatric patients with generalized pustular psoriasis (GPP).Materials and methods: A retrospective study was conducted from July 2021 to July 2024, including 10 children with GPP. Patients were divided into two age groups: chi...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2443121 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557043828228096 |
|---|---|
| author | Lu Xing Lingsheng Long Tao Wu Lingrui Yin Li Yu Jingnan Wu Danchen Li Limin Miao Hong Shu |
| author_facet | Lu Xing Lingsheng Long Tao Wu Lingrui Yin Li Yu Jingnan Wu Danchen Li Limin Miao Hong Shu |
| author_sort | Lu Xing |
| collection | DOAJ |
| description | Purpose: To evaluate the long-term efficacy and safety of secukinumab in pediatric patients with generalized pustular psoriasis (GPP).Materials and methods: A retrospective study was conducted from July 2021 to July 2024, including 10 children with GPP. Patients were divided into two age groups: children aged 0–3 years received 75 mg of secukinumab, while those aged 3–12 years received 150 mg. Secukinumab was administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by maintenance every 4 weeks. Treatment response was evaluated using the Generalized Pustular Psoriasis Area and Severity Index (GPPASI), Japanese Dermatological Association (JDA) score, and Infants’/Children’s Dermatology Life Quality Index (IDLQI/CDLQI).Results: By week 1, all patients achieved GPPASI-50 and mild JDA scores. By week 2, eight patients reached GPPASI-100, and nine achieved JDA scores of 0/1. Between weeks 12 and 70, all patients maintained GPPASI-100 and JDA scores of 0. Minimal relapses occurred in four patients, and one experienced five flares. The mean IDLQI/CDLQI improved from 21.8 at baseline to 0.4 by week 4, with sustained improvements throughout.Conclusions: Secukinumab demonstrated long-term efficacy and safety in pediatric GPP, significantly improving clinical outcomes and quality of life, with no serious adverse events reported. |
| format | Article |
| id | doaj-art-c61de4e65d8e4b95b26e9d992de87b8a |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-c61de4e65d8e4b95b26e9d992de87b8a2025-01-07T00:58:11ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2024.2443121Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world studyLu Xing0Lingsheng Long1Tao Wu2Lingrui Yin3Li Yu4Jingnan Wu5Danchen Li6Limin Miao7Hong Shu8Department of Dermatology, Children’s Hospital Affiliated to Kunming Medical University, Kunming, ChinaDepartment of Dermatology, Children’s Hospital Affiliated to Kunming Medical University, Kunming, ChinaDepartment of Colorectal Surgery, Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, ChinaDepartment of Dermatology, Children’s Hospital Affiliated to Kunming Medical University, Kunming, ChinaDepartment of Dermatology, Children’s Hospital Affiliated to Kunming Medical University, Kunming, ChinaDepartment of Dermatology, Children’s Hospital Affiliated to Kunming Medical University, Kunming, ChinaDepartment of Dermatology, Children’s Hospital Affiliated to Kunming Medical University, Kunming, ChinaDepartment of Dermatology, Children’s Hospital Affiliated to Kunming Medical University, Kunming, ChinaDepartment of Dermatology, Children’s Hospital Affiliated to Kunming Medical University, Kunming, ChinaPurpose: To evaluate the long-term efficacy and safety of secukinumab in pediatric patients with generalized pustular psoriasis (GPP).Materials and methods: A retrospective study was conducted from July 2021 to July 2024, including 10 children with GPP. Patients were divided into two age groups: children aged 0–3 years received 75 mg of secukinumab, while those aged 3–12 years received 150 mg. Secukinumab was administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by maintenance every 4 weeks. Treatment response was evaluated using the Generalized Pustular Psoriasis Area and Severity Index (GPPASI), Japanese Dermatological Association (JDA) score, and Infants’/Children’s Dermatology Life Quality Index (IDLQI/CDLQI).Results: By week 1, all patients achieved GPPASI-50 and mild JDA scores. By week 2, eight patients reached GPPASI-100, and nine achieved JDA scores of 0/1. Between weeks 12 and 70, all patients maintained GPPASI-100 and JDA scores of 0. Minimal relapses occurred in four patients, and one experienced five flares. The mean IDLQI/CDLQI improved from 21.8 at baseline to 0.4 by week 4, with sustained improvements throughout.Conclusions: Secukinumab demonstrated long-term efficacy and safety in pediatric GPP, significantly improving clinical outcomes and quality of life, with no serious adverse events reported.https://www.tandfonline.com/doi/10.1080/09546634.2024.2443121Generalized pustular psoriasisGPPinterleukin 17pediatriclong-termsecukinumab |
| spellingShingle | Lu Xing Lingsheng Long Tao Wu Lingrui Yin Li Yu Jingnan Wu Danchen Li Limin Miao Hong Shu Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study Journal of Dermatological Treatment Generalized pustular psoriasis GPP interleukin 17 pediatric long-term secukinumab |
| title | Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study |
| title_full | Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study |
| title_fullStr | Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study |
| title_full_unstemmed | Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study |
| title_short | Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study |
| title_sort | long term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis a real world study |
| topic | Generalized pustular psoriasis GPP interleukin 17 pediatric long-term secukinumab |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2443121 |
| work_keys_str_mv | AT luxing longtermefficacyandsafetyanalysisofsecukinumabinthetreatmentofpediatricgeneralizedpustularpsoriasisarealworldstudy AT lingshenglong longtermefficacyandsafetyanalysisofsecukinumabinthetreatmentofpediatricgeneralizedpustularpsoriasisarealworldstudy AT taowu longtermefficacyandsafetyanalysisofsecukinumabinthetreatmentofpediatricgeneralizedpustularpsoriasisarealworldstudy AT lingruiyin longtermefficacyandsafetyanalysisofsecukinumabinthetreatmentofpediatricgeneralizedpustularpsoriasisarealworldstudy AT liyu longtermefficacyandsafetyanalysisofsecukinumabinthetreatmentofpediatricgeneralizedpustularpsoriasisarealworldstudy AT jingnanwu longtermefficacyandsafetyanalysisofsecukinumabinthetreatmentofpediatricgeneralizedpustularpsoriasisarealworldstudy AT danchenli longtermefficacyandsafetyanalysisofsecukinumabinthetreatmentofpediatricgeneralizedpustularpsoriasisarealworldstudy AT liminmiao longtermefficacyandsafetyanalysisofsecukinumabinthetreatmentofpediatricgeneralizedpustularpsoriasisarealworldstudy AT hongshu longtermefficacyandsafetyanalysisofsecukinumabinthetreatmentofpediatricgeneralizedpustularpsoriasisarealworldstudy |